Li Z, Ran Q, Qu C, Hu S, Cui S, Zhou Y
Biol Direct. 2025; 20(1):23.
PMID: 40001213
PMC: 11853590.
DOI: 10.1186/s13062-025-00617-y.
Gao R, Hu X, Zhou Q, Hou X, Cao C, Tang G
JACS Au. 2024; 4(9):3641-3648.
PMID: 39328742
PMC: 11423299.
DOI: 10.1021/jacsau.4c00611.
Duengo S, Muhajir M, Hidayat A, Musa W, Maharani R
Molecules. 2023; 28(24).
PMID: 38138507
PMC: 10745333.
DOI: 10.3390/molecules28248017.
Xu B, Pan Q, Pan H, Li H, Li X, Chen J
EClinicalMedicine. 2023; 64:102240.
PMID: 37767191
PMC: 10520347.
DOI: 10.1016/j.eclinm.2023.102240.
Ressing M, Becker C, Muller C, Mahmoudpour S, Calaminus G, Langer T
Cancer Rep (Hoboken). 2023; 6(5):e1811.
PMID: 36975206
PMC: 10172172.
DOI: 10.1002/cnr2.1811.
Magneto-Fluorescent Mesoporous Nanocarriers for the Dual-Delivery of Ofloxacin and Doxorubicin to Tackle Opportunistic Bacterial Infections in Colorectal Cancer.
Marcelo G, Galhano J, Robalo T, Cruz M, Marcos M, Martinez-Manez R
Int J Mol Sci. 2022; 23(20).
PMID: 36293142
PMC: 9603674.
DOI: 10.3390/ijms232012287.
Clinical features of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single-center, retrospective observational study.
Nakayama T, Oshima Y, Kusumoto S, Yamamoto J, Osaga S, Fujinami H
EJHaem. 2022; 1(2):498-506.
PMID: 35845008
PMC: 9176145.
DOI: 10.1002/jha2.110.
The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial.
Liu D, Wu J, Lin C, Ding S, Lu S, Fang Y
Cancers (Basel). 2022; 14(13).
PMID: 35804991
PMC: 9264845.
DOI: 10.3390/cancers14133221.
Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma.
Nakayama T, Oshima Y, Shintani Y, Yamamoto J, Yokoi M, Ito T
Circ Rep. 2022; 4(4):173-182.
PMID: 35434414
PMC: 8977195.
DOI: 10.1253/circrep.CR-21-0145.
Synthetic (,-Dimethyl)doxorubicin Glycosyl Diastereomers to Dissect Modes of Action of Anthracycline Anticancer Drugs.
Wander D, van der Zanden S, Vriends M, van Veen B, Vlaming J, Bruyning T
J Org Chem. 2021; 86(8):5757-5770.
PMID: 33783212
PMC: 8056385.
DOI: 10.1021/acs.joc.1c00220.
Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives.
Prudner B, Ball T, Rathore R, Hirbe A
Neurooncol Adv. 2020; 2(Suppl 1):i40-i49.
PMID: 32642731
PMC: 7317062.
DOI: 10.1093/noajnl/vdz047.
Cytotoxic-induced heart failure among breast cancer patients in Nigeria: A call to prevent today's cancer patients from being tomorrow's cardiac patients.
Anakwue R
Ann Afr Med. 2020; 19(1):1-7.
PMID: 32174608
PMC: 7189886.
DOI: 10.4103/aam.aam_24_19.
Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE).
Ehrhardt M, Howell C, Hale K, Baassiri M, Rodriguez C, Wilson C
J Clin Oncol. 2019; 37(19):1647-1656.
PMID: 31075046
PMC: 6804891.
DOI: 10.1200/JCO.18.01099.
Validation of a 16th Century Traditional Chinese Medicine Use of as a Topical Antimicrobial.
Chassagne F, Huang X, Lyles J, Quave C
Front Microbiol. 2019; 10:775.
PMID: 31057504
PMC: 6478001.
DOI: 10.3389/fmicb.2019.00775.
Impact of Anthracyclines on Diabetes Mellitus Development in B-Cell Lymphoma Patients: A Nationwide Population-based Study.
Teng C, Chang K, Tsai I, Hwang W, Hsu C, Sheu W
Clin Drug Investig. 2018; 38(7):603-610.
PMID: 29633159
DOI: 10.1007/s40261-018-0645-1.
Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors.
Hirbe A, Cosper P, Dahiya S, Van Tine B
Sarcoma. 2017; 2017:3761292.
PMID: 28546782
PMC: 5435903.
DOI: 10.1155/2017/3761292.
Interaction of Anthracycline 3'-azido-epirubicin with Calf Thymus DNA via Spectral and Molecular Modeling Techniques.
Cui F, Niu X, Li L, Zhang P, Zhang G
J Fluoresc. 2015; 25(4):1109-15.
PMID: 26109510
DOI: 10.1007/s10895-015-1601-6.
Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.
Du F, Yuan P, Zhu W, Wang J, Ma F, Fan Y
Med Oncol. 2014; 31(12):340.
PMID: 25416049
DOI: 10.1007/s12032-014-0340-x.
Dose-dense epirubicin and cyclophosphamide followed by weekly Paclitaxel in node-positive breast cancer.
Mirzaei H, Nasrollahi F, Mohammadi Yeganeh L, Jafari Naeini S, Bikdeli P, Hajian P
Chemother Res Pract. 2014; 2014:259312.
PMID: 25276426
PMC: 4172875.
DOI: 10.1155/2014/259312.
Career readiness in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study.
Strauser D, Klosky J, Brinkman T, Wong A, Chan F, Lanctot J
J Cancer Surviv. 2014; 9(1):20-9.
PMID: 25047713
PMC: 4303554.
DOI: 10.1007/s11764-014-0380-4.
